Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2006

View Archived Issues

EAGLE study of Axxion stent meets primary endpoint

NicOx signs new ophthalmology agreement with Pfizer

Takeda selects cardiovascular target from Lexicon alliance

Nonapprovable letter for Emezine

Nastech reacquires rights to PYY3-36 nasal spray from Merck

Applied Biosystems completes acquisition of Ambion's Research Products Division

Keryx studies KRX-0401 for refractory leukemias

Sangamo licenses use of MaxCyte's cell loading system

Evizon 40 mg safe and active in stabilizing vision in wet AMD

Ganite effective compared with Aredia in cancer-related hypercalcemia

Oral NV-52 demonstrates rapid absorption and appreciable plasma levels

Endocannabinoid-derived topical treatment for atopic dermatitis

New inhibitor of PDGFR autophosphorylation for cell-proliferative disorders

Lucentis submitted for European approval for wet AMD

Novartis seeks European approval for Exforge

Priority review for Revlimid sNDA

Novel antiinfective agents covered in recent patents

Neupro receives approvable letter for early Parkinson's disease

Monoclonal antibody induces regression of HGF-dependent tumors in mice

Recent Pfizer, Gruenenthal and AstraZeneca patents report novel analgesic agents

Recent patents report novel agents for metabolic disorders

Clinical study of pollen extract preparation in CNBP/CPPS

R-850 shows good safety and efficacy profile in actinic keratosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...